| Variables | Favorable outcome | Statistical tests | ||
|
| Yes | No | ||
| Sex (N = 69) | Girls | 15 (31.25%) | 33 (58.75%) | P = 0.874 OR95% = 1.14 [0.42 - 4.07] |
| Boys | 6 (28.57%) | 15 (71.43%) | ||
| Age (years) (N = 69) | >10 | 12 (66.67%) | 6 (33.33%) | P = 0.001 OR95% = 9.93 [2.4 - 8.43] |
| <10 | 9 (17.65%) | 42 (82.35%) | ||
| Consultation time (months) (N = 69) | >6 | 13 (33.33%) | 26 (66.67%) | P = 0.57 OR95% = 1.38 [0.43 - 4.47] |
| <6 | 8 (26.67%) | 22 (73.33%) | ||
| Initial dose of ATD (mg/kg/d): (N = 69) | >1 | 15 (48.38%) | 16 (51.61%) | P = 0.024 OR95% = 2.71 [1.84 - 8.95] |
| <1 | 6 (15.79%) | 32 (84.21%) | ||
| Volume of goiter (N = 68) | Grade 2 | 13 (30.95%) | 29 (69.05%) | P = 0.98 OR95% = 1.01 [0.31 - 3.32] |
| Grade 0 - 1 | 8 (30.77%) | 18 (60.23%) | ||
| Protocol used (N = 69) | Protocol A | 14 (30.95%) | 28 (69.05%) | P = 0.818 OR95% = 1.14 [0.31 - 3.32] |
| Protocol B | 7 (25.93) | 20 (74.07) | ||
| Initial FT4 value (pmol/l) (N = 69) | >50 | 5 (13.16%) | 33 (86.84%) | P = 0.004 OR95% = 0.14 [0.04 - 0.52] |
| <50 | 16 (51.61%) | 15 (48.39%) | ||